05 to 06 November 2019

NICE, 10 Spring Gardens, London, SW1A 2BU

 Final Agenda – Day 1

The meeting will start promptly at 10:00 and is expected to finish at approximately 16:30.

Please note that this agenda is final and subject to change before the meeting.

The Public Health Advisory Committee (PHAC) meeting will be used to discuss evidence and make recommendations. The evidence being presented to the committee is from unpublished Cochrane reviews and therefore will take place in a part 2 session only (part 2 sessions are closed to public observers). Therefore, this meeting is not open to the public.

  1. Welcome, apologies, introductions and objectives – Part 2 only (closed session)
  2. Confirmation of matter under discussion, and declarations of interest in relation to the matter under discussion: Tobacco: preventing uptake, promoting quitting and treating dependence  Part 2 only (closed session)
  3. Minutes of the previous meeting  Part 2 only (closed session) 
  4. Review Question 6.4 – evidence review for long-term health effects of e-cigarettes  Part 2 only (closed session) 
    Presentation of the evidence  Part 2 only (closed session) 

  5. Review Question 6.4 – evidence review for long-term health effects of e-cigarettes  Part 2 only (closed session) 

    • Discussion and drafting of recommendations  Part 2 only (closed session) 
    • Call for evidence  Part 2 only (closed session) 
     
  6. Review Question 7.1 – smoking relapse prevention – Part 2 only (closed session)

    • Presentation of the evidence  Part 2 only (closed session) 
    • Discussion and clarity of evidence with Jonathan Livingstone-Banks, Nottingham University  Part 2 only (closed session) 
  7. Cost Effectiveness review for 7.1 smoking relapse prevention  Part 2 only (closed session) 

    • Presentation of the cost effectiveness evidence  Part 2 only (closed session) 
    • Question & answer  Part 2 only (closed session) 

  8. Review Question 7.1 – smoking relapse prevention.  Part 2 only (closed session) 

    • Discussion and drafting of recommendations  Part 2 only (closed session) 
    • Existing material and relevant areas  Part 2 only (closed session) 
    • Finalise recommendations  Part 2 only (closed session) 

  9. Question for the committee on:

    • RQ 5.3 evidence review for nicotine replacement therapies and e-cigarettes  Part 2 only (closed session) 
    • Preventing uptake section of guideline and additional recommendations  Part 2 only (closed session) 

  10. Review of day discussions and agreements of next steps – Part 2 only (closed session) 

Final Agenda – Day 2

The meeting will start promptly at 10:00 and is expected to finish at approximately 15:30.

Please note that this agenda is final and subject to change before the meeting.

The Public Health Advisory Committee (PHAC) meeting will be used to discuss evidence and make recommendations. The evidence being presented to the committee is from unpublished Cochrane reviews and therefore will take place in a part 2 session only (part 2 sessions are closed to public observers). Therefore, this meeting is not open to the public.

  1. Welcome, apologies, introductions and objectives – Part 2 only (closed session)
    Confirmation of matter under discussion, and declarations of interest in relation to the matter under discussion: Tobacco: preventing uptake, promoting quitting and treating dependence  Part 2 only (closed session)
  2. Review Question 5.3 – evidence review for nicotine replacement therapies and e-cigarettes in pregnancy  Part 2 only (closed session)

    Presentation of the qualitative evidence  Part 2 only (closed session)
    Discussion of the evidence with Kasia Campbell, Nottingham University  Part 2 only (closed session)

  3. Review Question 5.3 –cost effectiveness review for nicotine replacement therapies and e-cigarettes in pregnancy  Part 2 only (closed session)
    Presentation of the evidence and questions and answers  Part 2 only (closed session)

  4. Review Question 5.3 – evidence review for nicotine replacement therapies and e-cigarettes in pregnancy  Part 2 only (closed session)

    • presentation of the quantitative evidence  Part 2 only (closed session)
  5. Review Question 5.3 – review for nicotine replacement therapies and e-cigarettes in pregnancy  Part 2 only (closed session)
    • Discussion and clarity (with Tim Coleman & Ravinder Claire, Nottingham University)  Part 2 only (closed session) 
    • Proposed recommendations  Part 2 only (closed session) 
    • Existing sections  Part 2 only (closed session) 
    • Finalise recommendations  Part 2 only (closed session) 

  6. Review of day discussions and agreements of next steps – Part 2 only (closed session) 

To print this agenda, please right click and select ‘Print’ from the menu.

Date, time and venue of next meeting

The next meeting will take place on 14 & 15 January 2020, at NICE, 10 Spring Gardens, London, SW1A 2BU 

Please note all timings are approximate.